Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...
The American Journal of Managed Care4h
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Pharmaceutical Technology5h
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
Pharmaceutical Technology6h
Treating alcohol addiction: filling the medication gap
With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men ...
Lilly reports positive results for Omvoh in Crohn's disease
Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...
Malaysian Reserve5h
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Science Daily3h
Nutrition labels meant to promote healthy eating could discourage purchases
As the U.S. Food and Drug Administration weighs whether to require front-of-package food labels, a new study shows some food labels designed to nudge Americans toward healthier food choices can have ...